Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine if reducing or eliminating radiation treatment to one or both sides of the neck where there is no evidence of cancer can help spare the side effects of radiation treatment for head and neck cancer. In this study, the investigators plan to reduce the amount of radiation treatment received to healthy tissue
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intensity modulated radiation therapy (IMRT) | Experimental | -This study provides guidelines for volume to be contoured during IMRT based on tumor site and stage of tumor site. The clinical tumor volume (CTV)1 will be treated to 66 Cy in 33 fractions or 60 Gy in 30 fractions. The CTV2 will be treated to 54 Gy in 33 fractions or 52 Gy in 30 fractions. The CTV3 will be modified based on tumor site and stage of tumor site in order to reduce volume. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Intensity modulated radiation therapy | Radiation |
|
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With a Recurrence in the Unirradiated Neck(s) |
| 12 months of follow-up |
| Measure | Description | Time Frame |
|---|---|---|
| Kaplan Meier Estimate of Locoregional Recurrence Free Survival |
| 3 years |
| Quality of Life (QOL) as Measured by Overall Global QOL Scores |
Not provided
Inclusion Criteria:
Patients with pathologically proven tumors of the oral cavity, oropharynx, larynx, or hypopharynx .
Treated with surgical resection with one (or both) side(s) of the neck pathologically N0.
Indication for radiation therapy at the primary site or neck consisting of any of the below characteristics:
Age >= 18.
Patients must sign study specific, Institutional Review Board (IRB)-approved consent form.
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Wade Thorstad, MD | Washington University School of Medicine | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Washington University School of Medicine | St Louis | Missouri | 63110 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 10814959 | Background | Chao KS, Low DA, Perez CA, Purdy JA. Intensity-modulated radiation therapy in head and neck cancers: The Mallinckrodt experience. Int J Cancer. 2000 Apr 20;90(2):92-103. doi: 10.1002/(sici)1097-0215(20000420)90:23.0.co;2-9. | |
| 12527043 | Background | Chao KS, Ozyigit G, Tran BN, Cengiz M, Dempsey JF, Low DA. Patterns of failure in patients receiving definitive and postoperative IMRT for head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2003 Feb 1;55(2):312-21. doi: 10.1016/s0360-3016(02)03940-8. |
| Label | URL |
|---|---|
| Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The study opened to accrual on 04/11/2007 and closed to accrual 04/07/2014.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Arm 1: Intensity Modulated Radiation Therapy (IMRT) | -This study provides guidelines for volume to be contoured during IMRT based on tumor site and stage of tumor site. The clinical tumor volume (CTV)1 will be treated to 66 Cy in 33 fractions or 60 Gy in 30 fractions. The CTV2 will be treated to 54 Gy in 33 fractions or 52 Gy in 30 fractions. The CTV3 will be modified based on tumor site and stage of tumor site in order to reduce volume. |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Arm 1: Intensity Modulated Radiation Therapy (IMRT) | -This study provides guidelines for volume to be contoured during IMRT based on tumor site and stage of tumor site. The clinical tumor volume (CTV)1 will be treated to 66 Cy in 33 fractions or 60 Gy in 30 fractions. The CTV2 will be treated to 54 Gy in 33 fractions or 52 Gy in 30 fractions. The CTV3 will be modified based on tumor site and stage of tumor site in order to reduce volume. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Median |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of Participants With a Recurrence in the Unirradiated Neck(s) |
| Posted | Number | 95% Confidence Interval | participants | 12 months of follow-up |
|
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Arm 1: Intensity Modulated Radiation Therapy (IMRT) | -This study provides guidelines for volume to be contoured during IMRT based on tumor site and stage of tumor site. The clinical tumor volume (CTV)1 will be treated to 66 Cy in 33 fractions or 60 Gy in 30 fractions. The CTV2 will be treated to 54 Gy in 33 fractions or 52 Gy in 30 fractions. The CTV3 will be modified based on tumor site and stage of tumor site in order to reduce volume. |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Death NOS | General disorders | CTCAE (3.0) | Systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| ALT, SGPT | Investigations | CTCAE (3.0) | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Wade Thorstad, M.D. | Washington University School of Medicine | 314-362-8516 | thorstad@radonc.wustl.edu |
Not provided
| ID | Term |
|---|---|
| D007822 | Laryngeal Neoplasms |
| ID | Term |
|---|---|
| D010039 | Otorhinolaryngologic Neoplasms |
| D006258 | Head and Neck Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
Not provided
Not provided
| ID | Term |
|---|---|
| D050397 | Radiotherapy, Intensity-Modulated |
| ID | Term |
|---|---|
| D020266 | Radiotherapy, Conformal |
| D011881 | Radiotherapy, Computer-Assisted |
| D011878 | Radiotherapy |
| D013812 | Therapeutics |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
-The Quality of Life (QOL) Evaluation (Swallowing and Dryness Questionnaire) will be used. 20 questions with answers of Strongly Agree to Strongly Disagree. Global score was scaled for a total score from 0 to 100 with 0 being the worst QOL and 100 the best QOL. |
| Median follow-up was 22 months |
| Quality of Life (QOL) as Measured by Xerostomia QOL Data | -The Quality of Life (QOL) Evaluation (Swallowing and Dryness Questionnaire) will be used. 20 questions with answers of Strongly Agree to Strongly Disagree. Xerostomia score was scaled for a total xerostomia score from 0 to 100 with 0 being the worst QOL and 100 the best QOL. | Median follow-up was 22 months |
| Compare Standard Treatment Volume (CTV and PTV) With Protocol Defined Treatment Volume in Terms of Organ Specific Dose Volume Histograms | Completion of follow-up (minimum of 5 years from completion of treatment) |
| Disease Specific Survival Rate | Completion of follow-up (minimum of 5 years from completion of treatment) |
| Kaplan Meier Estimate of Overall Survival | 3 years |
| Patterns of Failure Associated With Implementation of Primary Objective | For patients who demonstrate a local failure during follow-up, a computed tomography (CT), positron emission tomography (PET)/CT, or magnetic resonance imagine (MRI) scan is fused with the original treatment planning CT scan using the computational environment for radiation research (CERR) developed at Washington University Medical Center. The methodology to transfer the digital imaging study via network to the radiation therapy research servers is mature. The original dose distribution and contours are correlated with the recurrent disease noted on the follow up imaging study. The recurrence is then classified as infield, marginal to the treatment field, or out of the treatment field depending on the dose received by the recurrent disease. Failures that occur in the treatment field are due to aspects of tumor biology rather than errors in the volume irradiated. As has been the case in our historical controls, the investigators expect most failures to be in the treatment field. | Completion of follow-up (minimum of 5 years from completion of treatment) |
| 11730997 | Background | Chao KS, Majhail N, Huang CJ, Simpson JR, Perez CA, Haughey B, Spector G. Intensity-modulated radiation therapy reduces late salivary toxicity without compromising tumor control in patients with oropharyngeal carcinoma: a comparison with conventional techniques. Radiother Oncol. 2001 Dec;61(3):275-80. doi: 10.1016/s0167-8140(01)00449-2. |
| 11240231 | Background | Chao KS, Deasy JO, Markman J, Haynie J, Perez CA, Purdy JA, Low DA. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results. Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):907-16. doi: 10.1016/s0360-3016(00)01441-3. |
| 11597795 | Background | Ang KK, Trotti A, Brown BW, Garden AS, Foote RL, Morrison WH, Geara FB, Klotch DW, Goepfert H, Peters LJ. Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2001 Nov 1;51(3):571-8. doi: 10.1016/s0360-3016(01)01690-x. |
| 11567806 | Background | O'Sullivan B, Warde P, Grice B, Goh C, Payne D, Liu FF, Waldron J, Bayley A, Irish J, Gullane P, Cummings B. The benefits and pitfalls of ipsilateral radiotherapy in carcinoma of the tonsillar region. Int J Radiat Oncol Biol Phys. 2001 Oct 1;51(2):332-43. doi: 10.1016/s0360-3016(01)01613-3. |
| 10435802 | Background | Jackson SM, Hay JH, Flores AD, Weir L, Wong FL, Schwindt C, Baerg B. Cancer of the tonsil: the results of ipsilateral radiation treatment. Radiother Oncol. 1999 May;51(2):123-8. doi: 10.1016/s0167-8140(99)00051-1. |
| 10562681 | Background | Brazilian Head and Neck Cancer Study Group. End results of a prospective trial on elective lateral neck dissection vs type III modified radical neck dissection in the management of supraglottic and transglottic carcinomas. Head Neck. 1999 Dec;21(8):694-702. doi: 10.1002/(sici)1097-0347(199912)21:83.0.co;2-b. |
| 15128893 | Background | Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Machtay M, Ensley JF, Chao KS, Schultz CJ, Lee N, Fu KK; Radiation Therapy Oncology Group 9501/Intergroup. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004 May 6;350(19):1937-44. doi: 10.1056/NEJMoa032646. |
| 15128894 | Background | Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefebvre JL, Greiner RH, Giralt J, Maingon P, Rolland F, Bolla M, Cognetti F, Bourhis J, Kirkpatrick A, van Glabbeke M; European Organization for Research and Treatment of Cancer Trial 22931. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004 May 6;350(19):1945-52. doi: 10.1056/NEJMoa032641. |
| 1907952 | Background | Perez CA, Carmichael T, Devineni VR, Simpson JR, Frederickson J, Sessions D, Spector G, Fineberg B. Carcinoma of the tonsillar fossa: a nonrandomized comparison of irradiation alone or combined with surgery: long-term results. Head Neck. 1991 Jul-Aug;13(4):282-90. doi: 10.1002/hed.2880130404. |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| Primary tumor type | Number | participants |
|
| Tobacco abuse | Number | participants |
|
| Counts |
|---|
| Participants |
|
|
| Secondary | Kaplan Meier Estimate of Locoregional Recurrence Free Survival |
| Posted | Number | percentage of participants-Kaplan Meier | 3 years |
|
|
|
| Secondary | Quality of Life (QOL) as Measured by Overall Global QOL Scores | -The Quality of Life (QOL) Evaluation (Swallowing and Dryness Questionnaire) will be used. 20 questions with answers of Strongly Agree to Strongly Disagree. Global score was scaled for a total score from 0 to 100 with 0 being the worst QOL and 100 the best QOL. | 65 out of 73 patients had evaluable QOL data in Arm 1. | Posted | Mean | Standard Deviation | units on a scale | Median follow-up was 22 months |
|
|
|
| Secondary | Quality of Life (QOL) as Measured by Xerostomia QOL Data | -The Quality of Life (QOL) Evaluation (Swallowing and Dryness Questionnaire) will be used. 20 questions with answers of Strongly Agree to Strongly Disagree. Xerostomia score was scaled for a total xerostomia score from 0 to 100 with 0 being the worst QOL and 100 the best QOL. | Posted | Mean | Standard Deviation | units on a scale | Median follow-up was 22 months |
|
|
|
| Secondary | Compare Standard Treatment Volume (CTV and PTV) With Protocol Defined Treatment Volume in Terms of Organ Specific Dose Volume Histograms | Not Posted | Apr 2026 | Completion of follow-up (minimum of 5 years from completion of treatment) | Participants |
| Secondary | Disease Specific Survival Rate | Not Posted | Apr 2026 | Completion of follow-up (minimum of 5 years from completion of treatment) | Participants |
| Secondary | Kaplan Meier Estimate of Overall Survival | Posted | Number | percentage of participants-Kaplan Meier | 3 years |
|
|
|
| Secondary | Patterns of Failure Associated With Implementation of Primary Objective | For patients who demonstrate a local failure during follow-up, a computed tomography (CT), positron emission tomography (PET)/CT, or magnetic resonance imagine (MRI) scan is fused with the original treatment planning CT scan using the computational environment for radiation research (CERR) developed at Washington University Medical Center. The methodology to transfer the digital imaging study via network to the radiation therapy research servers is mature. The original dose distribution and contours are correlated with the recurrent disease noted on the follow up imaging study. The recurrence is then classified as infield, marginal to the treatment field, or out of the treatment field depending on the dose received by the recurrent disease. Failures that occur in the treatment field are due to aspects of tumor biology rather than errors in the volume irradiated. As has been the case in our historical controls, the investigators expect most failures to be in the treatment field. | Not Posted | Apr 2026 | Completion of follow-up (minimum of 5 years from completion of treatment) | Participants |
| Post-Hoc | Kaplan Meier Estimate of Regional Recurrence Free Survival | -Recurrence is defined as the return of cancer after treatment | Posted | Number | percentage of participants-Kaplan Meier | 3 years |
|
|
|
| Post-Hoc | Kaplan Meier Estimate of Progression-free Survival | -Progression is defined using Response Evaluation Criteria in Solid Tumors (RECIST 1.0) as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. | Posted | Number | percentage of participants-Kaplan Meier | 3 years |
|
|
|
| 7 |
| 72 |
| 72 |
| 72 |
| Edema: head and neck | General disorders | CTCAE (3.0) | Systematic Assessment |
|
| Nausea | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
|
| Cough | Respiratory, thoracic and mediastinal disorders | CTCAE (3.0) | Systematic Assessment |
|
| Neck pain | Musculoskeletal and connective tissue disorders | CTCAE (3.0) | Systematic Assessment |
|
| Vomiting | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
|
| Dyspnea | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
|
| Hypoglycemia | Metabolism and nutrition disorders | CTCAE (3.0) | Systematic Assessment |
|
| Confusion | Psychiatric disorders | CTCAE (3.0) | Systematic Assessment |
|
| Psychosis | Psychiatric disorders | CTCAE (3.0) | Systematic Assessment |
|
| Hypercalcemia | Metabolism and nutrition disorders | CTCAE (3.0) | Systematic Assessment |
|
| Dehydration | Metabolism and nutrition disorders | CTCAE (3.0) | Systematic Assessment |
|
| Platelets | Investigations | CTCAE (3.0) | Systematic Assessment |
|
| Fever | General disorders | CTCAE (3.0) | Systematic Assessment |
|
| Hypoxia | Respiratory, thoracic and mediastinal disorders | CTCAE (3.0) | Systematic Assessment |
|
| Infection - catheter | Infections and infestations | CTCAE (3.0) | Systematic Assessment |
|
| Mucositis - oral cavity | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
|
| Rash (erythema) | Skin and subcutaneous tissue disorders | CTCAE (3.0) | Systematic Assessment |
|
| Hematoma | Vascular disorders | CTCAE (3.0) | Systematic Assessment |
|
| Anorexia | Metabolism and nutrition disorders | CTCAE (3.0) | Systematic Assessment |
|
| Oral cavity pain | Musculoskeletal and connective tissue disorders | CTCAE (3.0) | Systematic Assessment |
|
| Constipation | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
|
| Renal failure | Renal and urinary disorders | CTCAE (3.0) | Systematic Assessment |
|
| Hemolysis | Blood and lymphatic system disorders | CTCAE (3.0) | Systematic Assessment |
|
| Generalized weakness | General disorders | CTCAE (3.0) | Systematic Assessment |
|
| Deep vein thrombosis | Vascular disorders | CTCAE (3.0) | Systematic Assessment |
|
| Hyponatremia | Metabolism and nutrition disorders | CTCAE (3.0) | Systematic Assessment |
|
| ALT, SGPT (late radiation morbidity) | Investigations | CTCAE (3.0) | Systematic Assessment |
|
| ANC/Neutrophils (late radiation morbidity) | Investigations | CTCAE (3.0) | Systematic Assessment |
|
| AST, SGOT | Investigations | CTCAE (3.0) | Systematic Assessment |
|
| AST, SGOT (late radiation morbidity) | Investigations | CTCAE (3.0) | Systematic Assessment |
|
| Abdomen pain (late radiation morbidity) | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
|
| Abdominal pain | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
|
| Albumin (late radiation morbidity) | Metabolism and nutrition disorders | CTCAE (3.0) | Systematic Assessment |
|
| Albumin, serum-low | Metabolism and nutrition disorders | CTCAE (3.0) | Systematic Assessment |
|
| Alkaline phosphatase | Investigations | CTCAE (3.0) | Systematic Assessment |
|
| Allergic rhinitis | Immune system disorders | CTCAE (3.0) | Systematic Assessment |
|
| Anorexia | Metabolism and nutrition disorders | CTCAE (3.0) | Systematic Assessment |
|
| Anorexia (late radiation morbidity) | Metabolism and nutrition disorders | CTCAE (3.0) | Systematic Assessment |
|
| Apnea (late radiation morbidity) | Nervous system disorders | CTCAE (3.0) | Systematic Assessment |
|
| Arm pain (late radiation morbidity) | Musculoskeletal and connective tissue disorders | CTCAE (3.0) | Systematic Assessment |
|
| Aspiration | Respiratory, thoracic and mediastinal disorders | CTCAE (3.0) | Systematic Assessment |
|
| Aspiration pneumonia secondary to squamous cell carcinoma (late radiation morbidity) | Respiratory, thoracic and mediastinal disorders | CTCAE (3.0) | Systematic Assessment |
|
| Back pain (late radiation morbidity) | Musculoskeletal and connective tissue disorders | CTCAE (3.0) | Systematic Assessment |
|
| Bilirubin (late radiation morbidity) | Investigations | CTCAE (3.0) | Systematic Assessment |
|
| Calcium, serum-high | Metabolism and nutrition disorders | CTCAE (3.0) | Systematic Assessment |
|
| Calcium, serum-low | Metabolism and nutrition disorders | CTCAE (3.0) | Systematic Assessment |
|
| Calcium, serum-low (late radiation morbidity) | Metabolism and nutrition disorders | CTCAE (3.0) | Systematic Assessment |
|
| Calcium, serum-low (late radiation morbidity) | Metabolism and nutrition disorders | CTCAE (3.0) | Systematic Assessment |
|
| Cardiac arrest (late radiation morbidity) | Cardiac disorders | CTCAE (3.0) | Systematic Assessment |
|
| Chest pain | Cardiac disorders | CTCAE (3.0) | Systematic Assessment |
|
| Chest/thorax NOS pain (late radiation morbidity) | Respiratory, thoracic and mediastinal disorders | CTCAE (3.0) | Systematic Assessment |
|
| Clavicle pain (late radiation morbidity) | Respiratory, thoracic and mediastinal disorders | CTCAE (3.0) | Systematic Assessment |
|
| Cognitive disturbance (late radiation morbidity) | Nervous system disorders | CTCAE (3.0) | Systematic Assessment |
|
| Confusion (late radiation morbidity) | Psychiatric disorders | CTCAE (3.0) | Systematic Assessment |
|
| Constipation | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
|
| Constipation (late radiation morbidity) | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
|
| Cough | Respiratory, thoracic and mediastinal disorders | CTCAE (3.0) | Systematic Assessment |
|
| Cough (late radiation morbidity) | Respiratory, thoracic and mediastinal disorders | CTCAE (3.0) | Systematic Assessment |
|
| Creatinine | Investigations | CTCAE (3.0) | Systematic Assessment |
|
| Creatinine (late radiation morbidity) | Investigations | CTCAE (3.0) | Systematic Assessment |
|
| Death NOS (late radiation morbidity) | General disorders | CTCAE (3.0) | Systematic Assessment |
|
| Dehydration | Metabolism and nutrition disorders | CTCAE (3.0) | Systematic Assessment |
|
| Diarrhea | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
|
| Diarrhea (late radiation morbidity) | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
|
| Dizziness | Nervous system disorders | CTCAE (3.0) | Systematic Assessment |
|
| Dizziness (late radiation morbidity) | Nervous system disorders | CTCAE (3.0) | Systematic Assessment |
|
| Dry mouth (late radiation morbidity) | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
|
| Dry mouth/salivary gland | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
|
| Dysphagia | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
|
| Dysphagia (late radiation morbidity) | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
|
| Dyspnea | Respiratory, thoracic and mediastinal disorders | CTCAE (3.0) | Systematic Assessment |
|
| Dyspnea (late radiation morbidity) | Respiratory, thoracic and mediastinal disorders | CTCAE (3.0) | Systematic Assessment |
|
| Ear hemorrhage/bleeding | Ear and labyrinth disorders | CTCAE (3.0) | Systematic Assessment |
|
| Ear pain (late radiation morbidity) | Ear and labyrinth disorders | CTCAE (3.0) | Systematic Assessment |
|
| Edema: head and neck | General disorders | CTCAE (3.0) | Systematic Assessment |
|
| Edema: head and neck (late radiation morbidity) | General disorders | CTCAE (3.0) | Systematic Assessment |
|
| Edema: larynx | Respiratory, thoracic and mediastinal disorders | CTCAE (3.0) | Systematic Assessment |
|
| Edema: limb (late radiation morbidity) | General disorders | CTCAE (3.0) | Systematic Assessment |
|
| Edema: oropharynx | General disorders | CTCAE (3.0) | Systematic Assessment |
|
| Erythema (late radiation morbidity) | Skin and subcutaneous tissue disorders | CTCAE (3.0) | Systematic Assessment |
|
| Esophagitis | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
|
| Face pain (late radiation morbidity) | Musculoskeletal and connective tissue disorders | CTCAE (3.0) | Systematic Assessment |
|
| Failure to thrive | General disorders | CTCAE (3.0) | Systematic Assessment |
|
| Fatigue | General disorders | CTCAE (3.0) | Systematic Assessment |
|
| Fatigue (late radiation morbidity) | General disorders | CTCAE (3.0) | Systematic Assessment |
|
| Fever | General disorders | CTCAE (3.0) | Systematic Assessment |
|
| Fever (late radiation morbidity) | General disorders | CTCAE (3.0) | Systematic Assessment |
|
| Fistula (late radiation morbidity) | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
|
| Generalized pain | General disorders | CTCAE (3.0) | Systematic Assessment |
|
| Glucose, serum-high | Metabolism and nutrition disorders | CTCAE (3.0) | Systematic Assessment |
|
| Glucose, serum-high (late radiation morbidity) | Metabolism and nutrition disorders | CTCAE (3.0) | Systematic Assessment |
|
| Hair loss/alopecia | Skin and subcutaneous tissue disorders | CTCAE (3.0) | Systematic Assessment |
|
| Hair loss/alopecia (late radiation morbidity) | Skin and subcutaneous tissue disorders | CTCAE (3.0) | Systematic Assessment |
|
| Headache | Nervous system disorders | CTCAE (3.0) | Systematic Assessment |
|
| Headache (late radiation morbidity) | Nervous system disorders | CTCAE (3.0) | Systematic Assessment |
|
| Hearing | Ear and labyrinth disorders | CTCAE (3.0) | Systematic Assessment |
|
| Hearing (late radiation morbidity) | Ear and labyrinth disorders | CTCAE (3.0) | Systematic Assessment |
|
| Heartburn/dyspepsia | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
|
| Hemoglobin | Blood and lymphatic system disorders | CTCAE (3.0) | Systematic Assessment |
|
| Hemoglobin (late radiation morbidity) | Blood and lymphatic system disorders | CTCAE (3.0) | Systematic Assessment |
|
| Hemorrhage pulmonary/upper respiratory (late radiation morbidity) | Respiratory, thoracic and mediastinal disorders | CTCAE (3.0) | Systematic Assessment |
|
| Hemorrhage, oral cavity (late radiation morbidity) | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
|
| Hemorrhoids (late radiation morbidity) | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
|
| Hyperpigmentation | Skin and subcutaneous tissue disorders | CTCAE (3.0) | Systematic Assessment |
|
| Hypertension (late radiation morbidity) | Vascular disorders | CTCAE (3.0) | Systematic Assessment |
|
| Hypotension | Vascular disorders | CTCAE (3.0) | Systematic Assessment |
|
| INR | Investigations | CTCAE (3.0) | Systematic Assessment |
|
| INR (late radiation morbidity) | Investigations | CTCAE (3.0) | Systematic Assessment |
|
| Induration/fibrosis | Skin and subcutaneous tissue disorders | CTCAE (3.0) | Systematic Assessment |
|
| Induration/fibrosis (late radiation morbidity) | Skin and subcutaneous tissue disorders | CTCAE (3.0) | Systematic Assessment |
|
| Infection with normal ANC or grade 1 or 2 neutrophils | Infections and infestations | CTCAE (3.0) | Systematic Assessment |
|
| Insomnia (late radiation morbidity) | Psychiatric disorders | CTCAE (3.0) | Systematic Assessment |
|
| Jaw pain (late radiation morbidity) | Musculoskeletal and connective tissue disorders | CTCAE (3.0) | Systematic Assessment |
|
| Joint function (stiff) | Musculoskeletal and connective tissue disorders | CTCAE (3.0) | Systematic Assessment |
|
| Leg pain | Musculoskeletal and connective tissue disorders | CTCAE (3.0) | Systematic Assessment |
|
| Leukocytes (late radiation morbidity) | Investigations | CTCAE (3.0) | Systematic Assessment |
|
| Leukocytes (total WBC) | Investigations | CTCAE (3.0) | Systematic Assessment |
|
| Libido (late radiation morbidity) | Reproductive system and breast disorders | CTCAE (3.0) | Systematic Assessment |
|
| Limb pain (late radiation morbidity) | Musculoskeletal and connective tissue disorders | CTCAE (3.0) | Systematic Assessment |
|
| Lymphopenia | Investigations | CTCAE (3.0) | Systematic Assessment |
|
| Lymphopenia (late radiation morbidity) | Investigations | CTCAE (3.0) | Systematic Assessment |
|
| Magnesium, serum-low | Metabolism and nutrition disorders | CTCAE (3.0) | Systematic Assessment |
|
| Metastatic disease (late radiation morbidity) | General disorders | CTCAE (3.0) | Systematic Assessment |
|
| Mood alteration: anxiety | Psychiatric disorders | CTCAE (3.0) | Systematic Assessment |
|
| Mood alteration: anxiety (late radiation morbidity) | Psychiatric disorders | CTCAE (3.0) | Systematic Assessment |
|
| Mood alteration: depression | Psychiatric disorders | CTCAE (3.0) | Systematic Assessment |
|
| Mood alteration: depression (late radiation morbidity) | Psychiatric disorders | CTCAE (3.0) | Systematic Assessment |
|
| Mouth (thrush) infection (late radiation morbidity) | Infections and infestations | CTCAE (3.0) | Systematic Assessment |
|
| Mucositis (late radiation morbidity) | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
|
| Mucositis - oral cavity | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
|
| Mucositis - oropharynx | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
|
| Mucositis/stomatitis (functional) | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
|
| Mucositis/stomatitis - oral cavity (late radiation morbidity) | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
|
| Muscle weakness (late radiation morbidity) | Musculoskeletal and connective tissue disorders | CTCAE (3.0) | Systematic Assessment |
|
| Muscle weakness, generalized or specific area | Musculoskeletal and connective tissue disorders | CTCAE (3.0) | Systematic Assessment |
|
| Nausea | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
|
| Nausea (late radiation morbidity) | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
|
| Neck fistula (late radiation morbidity) | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
|
| Neck pain | Musculoskeletal and connective tissue disorders | CTCAE (3.0) | Systematic Assessment |
|
| Neck pain (late radiation morbidity) | Musculoskeletal and connective tissue disorders | CTCAE (3.0) | Systematic Assessment |
|
| Neuropathy: motor | Nervous system disorders | CTCAE (3.0) | Systematic Assessment |
|
| Neuropathy: sensory | Nervous system disorders | CTCAE (3.0) | Systematic Assessment |
|
| Neuropathy: sensory (late radiation morbidity) | Nervous system disorders | CTCAE (3.0) | Systematic Assessment |
|
| Neutrophils/Granulocytes | Investigations | CTCAE (3.0) | Systematic Assessment |
|
| Obstruction (late radiation morbidity) | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
|
| Oral cavity fibrosis (tongue) (late radiation morbidity) | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
|
| Oral cavity pain | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
|
| Oral cavity pain (late radiation morbidity) | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
|
| Oropharynx pain | Respiratory, thoracic and mediastinal disorders | CTCAE (3.0) | Systematic Assessment |
|
| Osteoradionecrosis (late radiation morbidity) | Musculoskeletal and connective tissue disorders | CTCAE (3.0) | Systematic Assessment |
|
| PTT (late radiation morbidity) | Investigations | CTCAE (3.0) | Systematic Assessment |
|
| Pericarditis | Cardiac disorders | CTCAE (3.0) | Systematic Assessment |
|
| Pharynx pain | Respiratory, thoracic and mediastinal disorders | CTCAE (3.0) | Systematic Assessment |
|
| Platelets | Investigations | CTCAE (3.0) | Systematic Assessment |
|
| Platelets (late radiation morbidity) | Investigations | CTCAE (3.0) | Systematic Assessment |
|
| Pneumonia | Infections and infestations | CTCAE (3.0) | Systematic Assessment |
|
| Pneumonia (late radiation morbidity) | Infections and infestations | CTCAE (3.0) | Systematic Assessment |
|
| Potassium (late radiation morbidity) | Metabolism and nutrition disorders | CTCAE (3.0) | Systematic Assessment |
|
| Potassium, serum-high | Metabolism and nutrition disorders | CTCAE (3.0) | Systematic Assessment |
|
| Potassium, serum-low (late radiation morbidity) | Metabolism and nutrition disorders | CTCAE (3.0) | Systematic Assessment |
|
| Pulmonary embolism | Respiratory, thoracic and mediastinal disorders | CTCAE (3.0) | Systematic Assessment |
|
| Radiation changes - pharynx/esophagus | Injury, poisoning and procedural complications | CTCAE (3.0) | Systematic Assessment |
|
| Rash - dermatitis (late radiation morbidity) | Skin and subcutaneous tissue disorders | CTCAE (3.0) | Systematic Assessment |
|
| Rash/desquamation | Skin and subcutaneous tissue disorders | CTCAE (3.0) | Systematic Assessment |
|
| Rash: erythema multiforme | Skin and subcutaneous tissue disorders | CTCAE (3.0) | Systematic Assessment |
|
| Rash: acne/acneiform | Skin and subcutaneous tissue disorders | CTCAE (3.0) | Systematic Assessment |
|
| Rash: dermatitis associated with radiation | Injury, poisoning and procedural complications | CTCAE (3.0) | Systematic Assessment |
|
| Rigors/chills (late radiation morbidity) | Investigations | CTCAE (3.0) | Systematic Assessment |
|
| Salivary gland changes, saliva (late radiation morbidity) | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
|
| Salivary gland changes/saliva | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
|
| Salivary glands (late radiation morbidity) | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
|
| Shoulder pain (late radiation morbidity) | Musculoskeletal and connective tissue disorders | CTCAE (3.0) | Systematic Assessment |
|
| Skin (late radiation morbidity) | Skin and subcutaneous tissue disorders | CTCAE (3.0) | Systematic Assessment |
|
| Skin changes | Skin and subcutaneous tissue disorders | CTCAE (3.0) | Systematic Assessment |
|
| Skin tightness (late radiation morbidity) | Skin and subcutaneous tissue disorders | CTCAE (3.0) | Systematic Assessment |
|
| Sodium, serum-high (late radiation morbidity) | Metabolism and nutrition disorders | CTCAE (3.0) | Systematic Assessment |
|
| Sodium, serum-low | Metabolism and nutrition disorders | CTCAE (3.0) | Systematic Assessment |
|
| Sodium, serum-low (late radiation morbidity) | Metabolism and nutrition disorders | CTCAE (3.0) | Systematic Assessment |
|
| Somnolence/depressed level of consciousness | Nervous system disorders | CTCAE (3.0) | Systematic Assessment |
|
| Speech impairment | Nervous system disorders | CTCAE (3.0) | Systematic Assessment |
|
| Speech impairment (late radiation morbidity) | Nervous system disorders | CTCAE (3.0) | Systematic Assessment |
|
| Syncope (late radiation morbidity) | Nervous system disorders | CTCAE (3.0) | Systematic Assessment |
|
| Taste alteration | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
|
| Teeth discoloration (late radiation morbidity) | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
|
| Telangiectasia | Skin and subcutaneous tissue disorders | CTCAE (3.0) | Systematic Assessment |
|
| Throat/larynx pain | Respiratory, thoracic and mediastinal disorders | CTCAE (3.0) | Systematic Assessment |
|
| Throat/pharynx/larynx pain (late radiation morbidity) | Respiratory, thoracic and mediastinal disorders | CTCAE (3.0) | Systematic Assessment |
|
| Thrombosis/thrombus/embolism (late radiation morbidity) | Vascular disorders | CTCAE (3.0) | Systematic Assessment |
|
| Tinnitus | Ear and labyrinth disorders | CTCAE (3.0) | Systematic Assessment |
|
| Tongue pain (late radiation morbidity) | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
|
| Tracheitis (late radiation morbidity) | Infections and infestations | CTCAE (3.0) | Systematic Assessment |
|
| Trismus | Musculoskeletal and connective tissue disorders | CTCAE (3.0) | Systematic Assessment |
|
| Trismus (late radiation morbidity) | Musculoskeletal and connective tissue disorders | CTCAE (3.0) | Systematic Assessment |
|
| Upper respiratory infection (late radiation morbidity) | Infections and infestations | CTCAE (3.0) | Systematic Assessment |
|
| Vision-blurred vision (late radiation morbidity) | Eye disorders | CTCAE (3.0) | Systematic Assessment |
|
| Voice changes/dysarthria | Respiratory, thoracic and mediastinal disorders | CTCAE (3.0) | Systematic Assessment |
|
| Voice changes/dysarthria (late radiation morbidity) | Respiratory, thoracic and mediastinal disorders | CTCAE (3.0) | Systematic Assessment |
|
| Vomiting | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
|
| Vomiting (late radiation morbidity) | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
|
| Watery eye | Eye disorders | CTCAE (3.0) | Systematic Assessment |
|
| Weight gain | Investigations | CTCAE (3.0) | Systematic Assessment |
|
| Weight loss | Investigations | CTCAE (3.0) | Systematic Assessment |
|
| Weight loss (late radiation morbidity) | General disorders | CTCAE (3.0) | Systematic Assessment |
|
| Wound complication, non infectious (late radiation morbidity) | Injury, poisoning and procedural complications | CTCAE (3.0) | Systematic Assessment |
|
Not provided
Not provided
Not provided
| D007818 |
| Laryngeal Diseases |
| D012140 | Respiratory Tract Diseases |
| D012142 | Respiratory Tract Neoplasms |
| D010038 | Otorhinolaryngologic Diseases |